본문바로가기
Language
Q
U
I
C
K

SK bioscience

SK bioscience is growing into a domestic and global vaccine developer by
continuously making investments and establishing infrastructure for vaccine development.

Message from the CEO

From prevention to cure,
SK bioscience is here to improve global health for mankind.

SK bioscience logo image Ahn Jae-yong

Chief Executive Officer, SK bioscience

Chief Executive Officer, SK bioscience, Ahn Jae-yong image
Welcome to SK bioscience.

SK bioscience is a spin off of SK Chemicals that specializes in vaccine development and manufacture. The foundation for the company’s growth was built by acquiring Dongshin Pharmaceuticals in 2001, establishing a vaccine R&D center in 2005, and constructing the Andong L House vaccine center in 2012.

With our corporate mission to “improve human health, from prevention to cure,” we have strengthened our leadership in the domestic market and build up our capacity to advance into the global market, while continuously pursuing a premium vaccine development strategy based on innovative technology.

SK bioscience’s achievements include: the development and the successful marketing of vaccines such as SKY Cellflu, the world’s first cell-cultured quadrivalent influenza vaccine; SKY Zoster, the world’s second shingles vaccine; and SKY Varicella, Korea’s only WHO prequalified varicella vaccine.

SK bioscience’s excellent vaccine R&D capabilities and manufacturing system is also attracting global attention.

In 2014, Sanofi Pasteur, the vaccine division of multinational pharmaceutical company Sanofi, signed a contract with SK bioscience for the co-development of a next-generation’s pneumococcal vaccine and, in 2018, the companies signed a contract to license out the technology for producing a cell culture-derived influenza vaccine.

International organizations, including the Bill & Melinda Gates Foundation (BMGF), PATH (Program for Appropriate Technology in Health), and IVI (International Vaccine Institute) are operating various vaccine R&D and manufacturing programs with SK bioscience.

Recently, domestic and foreign organizations such as the Korean Ministry of Health and Welfare, the Ministry of Trade, Industry and Energy, BMGF, and the CEPI (Coalition for Epidemic Preparedness Initiative) have come together to jointly develop COVID-19 vaccines, and global companies including AstraZeneca and Novavax have partnered with SK bioscience for the consignment production of COVID-19 vaccines at the state-of-the-art L House facility in Andong.

Having proven its competence throughout the entire vaccine business process, from development to production and commercialization, SK bioscience will further strengthen its efforts to create new market demand in the future.

In addition to the development of existing premium vaccines, we plan to secure new pipeline and platform technologies for preventive and therapeutic vaccines, and broaden our portfolio to the biopharmaceutical field.

At the same time, we plan to expand the global market by participating in overseas public vaccine bidding and advancing into developing countries, as well as establishing domestic and overseas bases and strengthening partnerships to cultivate the CMO (contract manufacturing) and CDMO (contract development and manufacturing) business.

SK bioscience will secure competitiveness as a leading global vaccine and biopharmaceutical company by building a complementary and sustainable business structure based on three areas: vaccines, biopharmaceuticals, and CMO/CDMO.

Through these efforts, we will ensure the satisfaction of all stakeholders, including employees, customers, shareholders, and local communities.

Thank you.

Chief Executive Officer, SK bioscience, Ahn Jae-yong